AxoSim Appoints Alif Saleh as Chief Executive Officer to Drive Market Adoption [Yahoo! Finance]
Lumos Pharma, Inc. (LUMO)
Company Research
Source: Yahoo! Finance
NEW ORLEANS June 11, 2024 /PRNewswire/ -- AxoSim, a life science company building human brains in the lab at scale to heal memory, movement, and pain disorders, today announced the appointment of Alif Saleh as chief executive officer. With this appointment, co-founder and previous CEO Lowry Curley, PhD, steps into the role of chief scientific officer. Saleh joins the AxoSim board of directors, and Curley continues to serve as a member. "I am thrilled Alif chose to join us for our next chapter of growth and scale," said Curley. "His expertise and strong commercial background will accelerate our leadership in the field. I am excited to increase my focus on AxoSim's science and technology." Saleh is a company builder who has raised half a billion dollars in funding to develop and commercialize novel technologies in the life science and biotechnology industry. In 2022, The Healthcare Technology Report recognized him as one of the "Top 50 Healthcare Technology CEOs." Saleh was previou
Show less
Read more
Impact Snapshot
Event Time:
LUMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUMO alerts
High impacting Lumos Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LUMO
News
- Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 [Yahoo! Finance]Yahoo! Finance
- Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024GlobeNewswire
- Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024 [Yahoo! Finance]Yahoo! Finance
- Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024GlobeNewswire
- Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
LUMO
Earnings
- 5/14/24 - Miss
LUMO
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- LUMO's page on the SEC website